← All trials
NCT05097261
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 6, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 28, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Katholieke Universiteit LeuvenLead sponsor
- Imelda Hospital, BonheidenCollaborator
- Katholieke Universiteit LeuvenSponsor investigator
- AZ Sint-JanCollaborator
- CHR CitadelleCollaborator
- University of LiegeCollaborator
- AZ Delta RoeselareCollaborator
- AZ TurnhoutCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.